why choose us

First received: September 23, 2022

Clinical Trial: A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed/Refractory Aggressive B-Cell Malignancies

Study Type: INTERVENTIONAL


Official Title: Phase 1/2 Multi-Center Study to Evaluate the Safety and Efficacy of ONCT-808 in Adult Subjects With Relapsed or Refractory Aggressive B-Cell Malignancies

Brief Summary: This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.

Read more